A 43-year-old woman reached an emergency department with colicky abdominal pain two weeks after her tirzepatide dose moved from 2.5 mg to 5 mg, and a CT scan showed a perforated duodenal ulcer in the third part of her duodenum. Her case, published in Cureus in September 2026, sits on the step the titration charts call easy.
Mounjaro dosage on the FDA label runs 2.5 mg once weekly to start, then 2.5 mg increases no sooner than four weeks apart, topping out at 15 mg in adults and 10 mg in patients 10 years and older. The climb is conditional. The label says to raise the dose “if additional glycemic control is needed.” That sentence is the article. Four weeks is a floor, and 15 mg is a limit, and neither is a finish line somebody owes you.
Mounjaro Dosage on the Label – 2.5 mg, Then Four Weeks That Do Not Compress
The current Mounjaro prescribing information, published by the National Library of Medicine’s DailyMed service on 2 September 2026, runs the schedule in three lines. Start at 2.5 mg subcutaneously once weekly. Increase by 2.5 mg after at least four weeks on the current dose. Stop at 15 mg for adults.
Read the same page for what the titration memes leave out. The dose goes once weekly, any time of day, with or without meals, into the abdomen, the thigh, or the back of the upper arm if someone else gives it, rotating sites. A missed dose goes in as soon as the patient remembers, provided four days have passed or fewer. Past four days, the dose gets skipped and the weekly rhythm resumes. The weekly day can shift as long as at least three days sit between two doses.
Then there is the part that matters for anyone drawing from a vial. The label lists six single-dose strengths at 0.5 mL each, and it also lists multi-dose vials and a single-patient-use KwikPen holding four doses at 0.6 mL per injection, with the 15 mg version running 25 mg per mL. That is a decimal point handled at a kitchen table, and the label answers it with one instruction: use a 1 mL syringe that can measure a 0.6 mL dose, and a new needle each time.
Four weeks is the only number on that page that cannot be rounded down for you.
Table 1 – Nausea Climbs From 4% to 18% With the Dose
The label’s own adverse reaction table, drawn from two placebo-controlled trials covering 718 adults with a mean exposure of 36.6 weeks, prints the cost of each step in a column.
Nausea: 4% on placebo, 12% at 5 mg, 15% at 10 mg, 18% at 15 mg. Diarrhea: 9%, then 12%, 13% and 17%. Vomiting: 2%, then 5%, 5% and 9%. Pool the gastrointestinal reactions and the shape gets starker. They hit 20.4% of placebo patients, 37.1% at 5 mg, 39.6% at 10 mg, and 43.6% at 15 mg. Discontinuation because of them: 0.4% on placebo, 3.0% at 5 mg, 5.4% at 10 mg, 6.6% at 15 mg.
One sentence there explains the two case reports below. The label states that the majority of nausea, vomiting and diarrhea reports came during dose escalation and decreased over time. The molecule does not turn hostile in month eight. The calendar does the work.
Two Labels, One Molecule – 2.5 mg Is Maintenance on One and Not the Other
Tirzepatide carries two FDA labels, and they disagree about the smallest dose in a way that matters to anyone reading a forum thread at midnight.
The Mounjaro label treats 2.5 mg as a legitimate place to stay. Its escalation clause is conditional on glycemic control, and nothing in the dosage section says the starting dose cannot be a maintenance dose.
The Zepbound label, published the same day and covering the same molecule, says the opposite in plain words: “The 2.5 mg dosage is for treatment initiation and is not approved as a maintenance dosage.” Its maintenance ladder reads 5 mg, 10 mg or 15 mg for weight reduction, 10 mg or 15 mg for sleep apnea, and 15 mg as the maximum.
Same molecule. Two instruction sheets. The answer to “can I stay at 2.5 mg” depends on which box the pharmacy picked up, and on a prescriber’s read of why the patient takes it. A directory page cannot settle that. A label comparison at least shows the question is real.
Mounjaro Dosage in a 43-Year-Old Woman – A Perforation Two Weeks After the Step
The Cureus report from September 2026 describes a woman on tirzepatide for weight loss who arrived with colicky abdominal pain two weeks after her dose went from 2.5 mg to 5 mg once weekly. Imaging showed a localised retroperitoneal perforation of a duodenal ulcer involving the third portion of the duodenum. Clinicians treated her with intravenous antibiotics, a proton pump inhibitor and bowel rest. She improved and went home without surgery.
The authors wrote the caveat themselves, and it deserves repeating in their spirit: one case cannot establish that tirzepatide caused the perforation. The temporal relationship is what they flagged, and what they asked for is more surveillance of upper gastrointestinal events in people taking the drug.
A case report is a signal with a date on it. This one carries a date two weeks after a dose increase.
Mounjaro Dosage in a 30-Year-Old Woman – One Week Between Steps, Then Intensive Care
The second report, in the American Journal of Case Reports on 1 July 2026, is harder to read and easier to check against the label.
A 30-year-old woman with a body mass index of 24.8 and no history of diabetes obtained tirzepatide without a prescription and injected 2.5 mg weekly, then moved to 5 mg. She raised the dose one week after starting, where the label asks for four. Four days later she arrived with severe nausea, roughly ten vomiting episodes a day, poor intake and periumbilical pain.
Her labs read like a metabolic emergency: pH 7.15, bicarbonate 10.5 mEq/L, anion gap of 24, ketones at 4.5 mmol/L, and a glucose of 4.2 mmol/L, which is a normal blood sugar. Euglycemic ketoacidosis is the name for that combination, and it put her in an intensive care unit. She came off the drug, took dextrose, lactated Ringer’s solution, thiamine and antiemetics, and her anion gap closed and ketones normalised within 36 hours without insulin or bicarbonate.
The label’s four-week floor exists for this family of events. Two weeks is a schedule somebody improvised. One week is a schedule with no check behind it.
Children 10 and Older – the Ceiling Drops to 10 mg
The current label carries a pediatric indication for type 2 diabetes in patients 10 years and older, and it puts the maximum at 10 mg once weekly for that group. Adults get 15 mg.
That ceiling came with its own numbers. Ninety-seven pediatric patients received the drug for a mean of 39.9 weeks, at a mean age of 15 and 61% female. During the 30-week placebo-controlled stretch, vomiting ran 3% on placebo, 16% at 5 mg and 12% at 10 mg, and abdominal pain ran 9%, 22% and 15%. The label notes higher vomiting, abdominal pain and hypoglycemia in children than in adults.
A lower ceiling for smaller bodies is the least surprising line in the document. It is also the line a milligram-based price list cannot show you, because a vial does not come with an age printed on it.
What the Label Cannot Answer
Three things sit outside the evidence, and pretending otherwise repeats the sin of the titration charts.
First, causation. Two case reports describe serious harm close to a dose increase. Neither proves the drug did it. The perforation authors said so, and honest reading means holding the signal without upgrading it to proof.
Second, compressed schedules. No published trial has compared the label’s four-week floor against a faster climb, so no published rate exists for a patient who doubles the pace. The case reports are the entire public record on that question, and two patients are not a rate.
Third, compounded tirzepatide. A compounded product is not the approved drug, is not FDA-approved, and its content is not guaranteed by the label numbers above. Someone drawing a research vial runs a different experiment than the 718 adults in Table 1, with no table at the end of it.
An absent number is not a licence to invent one.
Frequently asked questions
What is the starting dose of Mounjaro?
2.5 mg injected subcutaneously once weekly, according to the Mounjaro label published 2 September 2026. The label calls that the recommended starting dosage and asks for at least four weeks on it before any increase.
Can I stay on 2.5 mg of Mounjaro?
On the Mounjaro label, yes: the dose rises only if additional glycemic control is needed. On the Zepbound label for the same molecule, no: that label states the 2.5 mg dose is for initiation and is not approved as a maintenance dosage. The label that applies depends on the indication your prescriber wrote.
How fast can I increase my Mounjaro dose?
No faster than 2.5 mg in any four-week window, per the label. The escalation paragraph reads “increase the dosage in 2.5 mg increments after at least 4 weeks on the current dose,” and it ties that pace to reducing gastrointestinal adverse reactions.
What happens if I miss a Mounjaro dose?
Take it within four days, or 96 hours, of the missed dose. Past that window, skip it and wait for the regular day. A patient can also move the weekly day as long as at least three days, or 72 hours, separate two doses.
Is 15 mg the Mounjaro dose that works best?
The label sets 15 mg as the adult maximum, not a target. Trial data behind the approval covers 5, 10 and 15 mg, and Table 1 shows gastrointestinal reactions climbing with each step, so a higher number buys glycemic effect at a measurable cost.
Can a compounded tirzepatide vial follow the same schedule?
The titration logic transfers in principle, and the safety numbers do not. Compounded tirzepatide is not an FDA-approved product, so the 718-patient table and the 15 mg ceiling describe the approved drug, not an unverified vial. Dose decisions belong to the prescriber who wrote it.
Sources: DailyMed, Mounjaro (tirzepatide) prescribing information, published 2 September 2026, DailyMed, Zepbound (tirzepatide) prescribing information, published 2 September 2026, Cureus, Duodenal ulcer perforation following tirzepatide injections, September 2026, American Journal of Case Reports, Starvation-type euglycemic ketoacidosis after unsupervised tirzepatide use, 1 July 2026.
The side-effect record behind these dose steps, counted by label rather than by forum, sits in tirzepatide side effects: 56% gut symptoms, one in 15 stop. The same escalation logic in a different molecule is in semaglutide side effects: the ladder does most of the damage, and the syringe question is in how to reconstitute peptides: 17 substances FDA flagged.
Compounded products are not FDA-approved and are not the drug described in these trials. This page reports what labels and published case reports say. It does not set doses, and dose decisions belong to a licensed prescriber who has seen the patient.